PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Marketed as 'black salve' for skin cancer, but clinical data primarily consist of case studies with unfavorable outcomes; however, preclinical studies suggest sanguinarine may be efficacious at micromolar doses [PMID:33128472, PMID:24175872].
Sanguinarine shows broad antimicrobial activity in vitro; however, clinical effectiveness of toothpastes and mouthwashes containing the extract against dental plaque and gingivitis has shown conflicting results [PMID:2700895, PMID:22318955].
In vitro studies indicate that bloodroot extracts can enhance proliferation and cytokine production (TNF, IL-1beta, IL-10) in human peripheral blood mononuclear cells [PMID:20111671, PMID:19766513].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 23169210 (2012) — Bloodroot. · Dermatitis : contact, atopic, occupational, drug
- 2.PMID: 34847001 (2021) — Botanical Briefs: Bloodroot (Sanguinaria canadensis). · Cutis
- 3.PMID: 25046467 (2014) — Bloodroot associated eschar. · Dermatology online journal
- 4.PMID: 33128472 (2021) — Dermatologic uses of bloodroot: a review and reappraisal. · International journal of dermatology
- 5.PMID: 27618894 (2016) — Sanguinaria canadensis: Traditional Medicine, Phytochemical Composition, Biological Activities and Current Uses. · International journal of molecular sciences